Vendor Intelligence Report: MT Meipept

Published 13 Jun 2026. 23-page investigative report on who is behind MT Meipept: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 11 Finnrick lab tests, MT Meipept’s overall pass rate is 73%. The tested catalog is narrow: Retatrutide is the stronger current signal, while Tirzepatide is weaker and more exposed to failures. The key lab issue is not simple identity failure; it is fill accuracy, with stricter grading less forgiving when small GLP-1 vials drift far from the label claim.

The corporate trail is unusually concrete for a new peptide storefront. MT Meipept’s own Terms of Service make Amino USA LLC the binding legal entity, and Texas records attach that entity to a named Houston principal. The weakness is physical-footprint evidence: the addresses surfaced in the file resolve to a mailbox service, registered-agent office, or residences, not a verifiable lab, warehouse, or fulfillment facility.

The storefront’s domestic-shipping message also sits beside foreign-facing technical and contact signals. The report documents a HiChina-registered domain, China-linked storefront indicators, a Gmail support address, and a Hong Kong phone number. Documentation credibility is another pressure point: MT Meipept publishes a QC page, but the text matches another vendor’s QC language, and other pages retain unrelated boilerplate and product copy-paste errors.

Bottom line: MT Meipept is more usable than an anonymous vendor with no independent testing, but it is not a strong default for precision-sensitive GLP-1 research. Retatrutide is the relatively better signal; Tirzepatide and low-dose vial purchases need stricter lot and vial-size verification.

Inside the full report:

  • Appendix A with per-product pass/fail rates and methodology-divergence charts for both tested products
  • Texas corporate-record timeline linking MT Meipept, Amino USA LLC, and named owner identifiers
  • Address verification for the Houston mailbox, Austin registered-agent office, and residential records
  • Domain and infrastructure analysis covering HiChina registration, storefront stack indicators, Gmail, Hong Kong contact rails, and meipept.org
  • QC plagiarism and copy-paste exhibits comparing the Science Bio text, stamp-shop boilerplate, and Retatrutide page error
  • Reputation and promotion review covering ScamAdviser, Amino USA sentiment, TikTok/Instagram/Facebook leads, and the X/web affiliate sweep

Risk assessment

  • Small-vial quantity overfill risk — high: Tirzepatide ≤15mg vials and Retatrutide 10mg vials showed +61.0% to +80.0% overfills in investigator-reviewed Finnrick records; label-based dosing is unsafe without lot/vial-size verification.
  • Documentation and QC credibility risk — high: Quality-control text matches Science Bio word for word, while About Us and Retatrutide pages contain unrelated boilerplate and copy-paste errors.
  • Physical-facility opacity risk — medium: Known addresses resolve to a mailbox service, registered-agent office, or residences; no verifiable lab, warehouse, or fulfillment facility surfaced.
  • Domestic-identity mismatch risk — medium: “USA-Domestic Delivery” and “Same-Day Shipping” claims sit beside HiChina registration, Chinese storefront infrastructure indicators, Gmail contact, and a Hong Kong phone number.
  • Brand-confusion and authenticity-verification risk — medium: meipept.org and similarly named social leads create ambiguity; the materials do not show a canonical official-channel list, authorized-reseller list, or robust anti-counterfeit verification.